Latest 10-K annual reports
AMEX
AtlasClear Holdings, Inc. filed an amended annual report for fiscal year 2025, reporting a significant shift to net income despite ongoing liquidity concerns and internal control weaknesses.
The Glimpse Group, Inc. reported a significant reduction in net loss and increased revenue for fiscal year 2025, driven by a strategic shift to Spatial Computing and divestiture of non-core assets.
NYSE
IDT
Idt CORPIDT Corporation's fiscal 2025 annual report highlights significant revenue and income growth across its fintech and communications segments, driven by strategic expansion and operational efficiencies.
NASDAQ
Propanc Biopharma, a biopharmaceutical company, reported a significant increase in net loss to $58.9 million for fiscal year 2025, driven by substantial stock-based compensation, while advancing its lead cancer drug candidate, PRP, towards Phase Ib clinical trials.
NASDAQ
BENF
BeneficientBeneficient reported a significantly reduced net loss for fiscal year 2025, driven by legal settlements and lower operating expenses, though substantial doubt about its ability to continue as a going concern persists.
NYSE
TRAK
Repositrak, INCReposiTrak, Inc. announced an 11% revenue increase and a 25% rise in net income for fiscal year 2025, alongside a 10% dividend increase and continued Preferred Stock redemptions.
NASDAQ
AMST
Amesite INCAmesite Inc. shifts its core business to AI-powered healthcare solutions with NurseMagic, reporting reduced net losses but facing substantial doubt about its ability to continue as a going concern.
AMEX
AtlasClear Holdings, Inc. reported a net income of $5.75 million for the fiscal year ended June 30, 2025, a significant improvement from the prior year's substantial loss, despite ongoing liquidity challenges and a 'going concern' warning.
NASDAQ
MacKenzie Realty Capital, Inc. reported a significantly wider net loss for fiscal year 2025, driven by increased expenses and an impairment loss, leading to the suspension of common stock dividends.
OQB
VIPZ
Vip Play, INCVIP Play, Inc. reported a net loss of $18.9 million for fiscal year 2025, a significant improvement from the prior year, but faces substantial doubt about its ability to continue as a going concern without further financing.
OQB
Bion Environmental Technologies, Inc. reports significant financial challenges and leadership changes, pivoting its strategy towards bolt-on ammonia control solutions after writing down its Fair Oaks demonstration facility.
Neuphoria Therapeutics Inc. reports progress in its clinical pipeline for neuropsychiatric disorders, including BNC210 in Phase 3 for SAD and Phase 2b/3 for PTSD, alongside a $15 million milestone payment from Merck.
OQB
Okmin Resources, Inc. reported a net loss of $597,167 for fiscal year 2025, reduced its Blackrock JV interest, and increased its stake in the Pushmataha Gas Field, while facing significant going concern doubts and capital constraints.
AMEX
NanoViricides, Inc. reports progress in broad-spectrum antiviral drug NV-387's clinical development, including Phase Ia/Ib completion, but faces significant financial constraints and a going concern doubt.
NASDAQ
Lesaka Technologies reports significant net losses and internal control weaknesses for fiscal 2025, despite revenue growth driven by strategic acquisitions and expansion in Southern Africa's fintech market.
OTC.Pink
Anebulo Pharmaceuticals is prioritizing the development of an intravenous selonabant formulation for pediatric cannabis poisoning, while reporting continued operating losses and proposing a reverse stock split to go private.
OQB
Escalon Medical Corp. reported a slight increase in net revenue for fiscal year 2025, but auditors continue to express substantial doubt about the company's ability to continue as a going concern.
NASDAQ
Precision Optics Corporation, Inc. reported a significant increase in net loss and a sharp decline in gross margin for the fiscal year ended June 30, 2025, despite flat revenues and successful capital raises.
NASDAQ
NEOV
Neovolta INCNeoVolta, Inc. announced a significant increase in annual revenue for fiscal year 2025, driven by sales channel expansion, but reported a more than doubling of its net loss and increased cash burn.
NYSE
Vail Resorts reports increased fiscal 2025 EBITDA and strategic capital investments, alongside a Whistler Blackcomb credit facility extension and reduction, while facing declining pass units and economic uncertainties.
NASDAQ
5E Advanced Materials progresses its Fort Cady boron and lithium project with a $435 million Phase 1 capital estimate, targeting 2028 commercial production, despite ongoing significant losses and substantial doubt about its ability to continue as a going concern.
NASDAQ
SRBK
Sr Bancorp, INCSR Bancorp, Inc. reported a significant increase in net income for the fiscal year ended June 30, 2025, driven by loan growth and strategic balance sheet restructuring, despite a material weakness in internal controls.
RENB
Renovaro INCLunai Bioworks Inc. reported a significant increase in net loss for fiscal year 2025, alongside a subsidiary's bankruptcy and ongoing legal challenges, raising substantial doubt about its ability to continue as a going concern.
OQB
Cavitation Technologies, Inc. reported a net loss of $113,000 for fiscal year 2025, a significant decline from the prior year's profit, as it shifts focus to new ventures in water treatment and alcoholic beverages.
OTC.Pink
Leafbuyer Technologies, Inc. reported a net profit of $260,672 for the fiscal year ended June 30, 2025, marking a significant turnaround from the previous year's loss, driven by revenue growth and cost efficiencies.
NASDAQ
NetSol Technologies reports a 7.6% revenue growth and a 327% increase in net income for FY 2025, driven by subscription and services growth.
OTC.Pink
C2 Blockchain, Inc. reported a significant net loss of $235,265 for fiscal year 2025, highlighting its development-stage status and reliance on external financing for future cryptocurrency mining and digital asset initiatives.
NASDAQ
Incannex Healthcare Inc. reported a significant increase in net loss for fiscal year 2025, driven by financing activities, while advancing its lead drug candidates IHL-42X and PSX-001 through clinical trials.
NASDAQ
Marine Petroleum Trust, a royalty trust, reported a slight increase in distributable income for fiscal year 2025, driven by higher natural gas and NGL royalties despite a decline in oil production and prices.
AMEX
Moving iMage Technologies, Inc. filed an amended annual report for fiscal year 2025, correcting an auditor report date and detailing a reduced net loss despite a revenue decline.